1-5 of 5
Julie S Larsen
Close
Save search
Sort by
Journal Articles

Teclistamab, Daratumumab, and Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Majestec-2 Cohort a and Trimm-2 Studies

Free
Anita D'Souza, Luciano J. Costa, Jesús F. San-Miguel, Jesus G Berdeja, Daniel Morillo Giles, Cyrille Touzeau, John T McKay, Bhagirathbhai Dholaria, Thomas G Martin, Aurore Perrot, Albert Oriol, Anna Sureda Balari, Thomas Prior, Debopriya Ghosh, Lijuan Kang, Julie S Larsen, Hein Ludlage, Lien Vandenberk, Lingling Chen, Bas D Koster, Weili Sun, Rachel Kobos, Emma Searle, Jeffrey V Matous, Ajai Chari, Tobias Kampfenkel
Journal: Blood
Blood (2024) 144 (Supplement 1): 495.
https://doi.org/10.1182/blood-2024-200181
Published: 2024
Journal Articles

Pharmacodynamic Signatures and Correlatives of Response in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Talquetamab or Teclistamab Plus Daratumumab and Pomalidomide

Free
Deeksha Vishwamitra, Sheri Skerget, Diana Cortes, Kalpana Bakshi, Lien Vandenberk, Weili Sun, Jaszianne Tolbert, Colleen Kane, Hein Ludlage, Bas D Koster, Julie S Larsen, Tobias Kampfenkel, Ching Li, Farheen Zishan, Thomas Prior, Luciano J. Costa, Jesus G Berdeja, Cyrille Touzeau, Aurore Perrot, Emma Searle, Jeffrey V Matous, Ajai Chari, Donna Reece, Manisha Bhutani, Bhagirathbhai Dholaria, Anita D'Souza, Thomas G Martin, John T. McKay, Alfred L Garfall, Amrita Y Krishnan, Niels W.C.J. van de Donk, Nizar J. Bahlis, Ricardo M. Attar
Journal: Blood
Blood (2024) 144 (Supplement 1): 594.
https://doi.org/10.1182/blood-2024-200300
Published: 2024
Journal Articles

Preliminary Results of a Multicenter Phase II Trial of 5-Day Decitabine as Front-Line Therapy for Elderly Patients with Acute Myeloid Leukemia (AML)

Free
Amanda F Cashen, MD, Gary J. Schiller, MD, FACP, Margaret R. O’Donnell, MD, Julie S. Larsen, PharmD, Akhil Baranwal, MD, Michael T Cullen, MD, John F DiPersio, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 560.
https://doi.org/10.1182/blood.V112.11.560.560
Published: 2008
Journal Articles

Preliminary Results of a Phase II Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults with Myelodysplastic Syndrome (MDS).

Free
David P. Steensma, MD, Maria R. Baer, MD, James L. Slack, MD, Rena Buckstein, MD, Lucy Godley, MD, PhD, Julie S. Larsen, Michael T. Cullen, MD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2007) 110 (11): 1450.
https://doi.org/10.1182/blood.V110.11.1450.1450
Published: 2007
Journal Articles

Phase II Study of Low-Dose Decitabine for the Front-Line Treatment of Older Patients with Acute Myeloid Leukemia (AML).

Free
Amanda Cashen, MD, Gary J. Schiller, MD, Julie S. Larsen, PharmD, Michael T. Cullen, Jr., MD, John F. DiPersio, MD, PhD
Journal: Blood
Blood (2006) 108 (11): 1984.
https://doi.org/10.1182/blood.V108.11.1984.1984
Published: 2006